Navigation Links
Transdermal Hormone Replacement: Products, Players, Markets and Forecasts
Date:5/29/2012

NEW YORK, May 29, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Transdermal Hormone Replacement: Products, Players, Markets and Forecasts http://www.reportlinker.com/p0868621/Transdermal-Hormone-Replacement-Products-Players-Markets-and-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of decreasing hormone levels have come to the forefront as a quality-of-life issue for patients and their families. For the past two decades, the healthcare industry has responded to this clinical need by developing, testing and marketing hormone replacement therapy (HRT) products. Because of their ease-of-use and dosing characteristics, drug developers are continuing to turn to transdermal delivery systems for HRT products. There are more than 40 million post-menopausal women in the United States alone, and this group is expected to grow by 50% by 2020. With the aging of the population worldwide, conditions and diseases such as menopause, osteoporosis and heart disease, which may benefit from hormone replacement therapy, are expected to become significantly more prevalent. The industry continues to attract interest in the form of new participants and products. While the global market continues to be dominated by the FDA-approved HRT products of major pharmaceutical firms, regional markets are a bit more competitive, and present unique challenges to transdermal HRT sector participants.

Highlights

· Analyzes and evaluates the global market opportunity for transdermal hormone replacement and assesses the probable impact of evolving regulatory, economic and demand factors

· Assesses transdermal products approved or in development for the delivery of therapeutic hormones

· Provides detailed descriptions of hormone replacement treatment segments, market factors, and business strategies

· Forecasts transdermal hormone replacement product demand to 2016 by geographic region and product segment

· Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners

Summary of Contents

Executive Summary

Scope and DefinitionsThe Hormone Replacement Therapy MarketThe Opportunity for Transdermal Hormone Replacement Therapy

The Hormone Replacement Therapy Market Opportunity

Evolution in HRT GuidelinesRegional Factors in HRT PracticeHormone Replacement Therapy Demand Drivers Competitive LandscapeFactors Limiting Growth

Transdermal Drug Delivery Dynamics

Transdermal HRT PatchesPatch Designs and ConstructionTransdermal Patch Manufacturing and PackagingThe Patch Manufacturing EcosystemPatch EconomicsTransdermal HRT GelsTransdermal FormulationsIP and Proprietary TechnologyLimitations of Topical Gels & EmulsionsTransdermal HRT Sprays

Transdermal HRT Indications and Markets

HypoestrogenismHypogonadismMenopauseVasomotor SymptomsVaginal AtrophyPostmenopausal Osteoporosis

Transdermal HRT Product Assessments and Market Prospects

Approved Transdermal HRT ProductsEstradiol  Ascend   Azur   Bayer Healthcare   Graceway   KV Pharm   Mylan   Novartis  Watson Laboratories   Upsher-Smith  Faran SA   Janssen-Cilag  Meda   Shiseido  Solvay Estradiol Levonorgestrel  Bayer HealthcareEstradiol/Norethindrone  Novartis Testosterone  Abbott Labs   Auxilium   Endo Pharms   Teva   Watson Laboratories Development-Stage Transdermal HRT ProductsEstrogenTestosteroneOther Hormones

Transdermal Hormone Replacement Market Factors 

Regional Regulations Clinical Trials Quality and ReliabilityIndications Prescribing Guidelines and Off-Label PrescribingManaged Care and Payor InitiativesRx-to-OTC Switching

Market Forecasts

Forecast MethodologyForecasts by RegionForecasts by Drug ClassForecasts by Delivery Form FactorMarket Share Data 

Market Participant Profiles

To order this report: Drug and Medication Industry: Transdermal Hormone Replacement: Products, Players, Markets and Forecasts

More Market Research Report

Check our Industry Analysis and Insights

__________________________
Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
2. Transdermal Drug Delivery - Technologies, Markets, and Companies
3. Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
4. EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System
5. Transdermal Drug Delivery - Technologies, Markets, and Companies
6. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
7. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
8. New Post Hoc Analyses Examined the Effects of Neupro® (Rotigotine Transdermal System) on Daytime Functioning, Daytime Symptoms, Pain and Mood in Restless Legs Syndrome
9. Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinsons Disease
10. Transdermal Drug Delivery - Technologies, Markets, and Companies
11. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):